By granting compulsory license to Natco for Bayer's kidney cancer drug Nexavar, the Indian government has opened a legal can of worms, reports CNBC-TV18's Archana Shukla.
first published: Aug 16, 2012 09:41 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
Can Nifty Claw Back Above 25,600 Or Will Sensex Expiry Cap The Upside?| Opening Bell Live
Gold ETFs vs Silver ETFs | Which One Is Your Wealth Buddy?
